Mechanism of RNA modification N6-methyladenosine in human cancer

Zhou, Zijian; Lv, Jiancheng; Yu, Hao; Han, Jie; Yang, Xiao; Feng, Dexiang; Wu, Qikai; Yuan, Baorui; Lu, Qiang; Yang, Haiwei

doi:10.1186/s12943-020-01216-3

Molecular Cancer

Table 4 The m6A protein alterations are correlated with clinicopathological features

From: Mechanism of RNA modification N6-methyladenosine in human cancer

Cancer	Regulator	Alteration	Prognosis	Metastasis/Invasion	Tumor size	Tumor stage	Histological grade	Recurrence	Therapy	Refs
AML	METTL3/ WTAP	Overexpression	Poor							[41, 43]
AML	METTL3/METTL14/YTHDF1/YTHDF2/FTO/ALKBH5	Mutation	Poor							[142]
GBM	METTL3	Overexpression	Poor						Radioresistance	[48]
GBM	WTAP/RBM15/YTHDF1/ ALBKH5	Overexpression	Poor				Increase			[49]
LC	METTL3	Overexpression	Poor	Lymph node metastasis Brain metastasis	Increase	Worsen				[54, 55]
LC	FTO/ IGF2BP1	Overexpression	Poor							[56, 59]
HCC	METTL3/YTHDF1	Overexpression	Poor			Worsen				[58, 121]
HCC	KIAA1429/ IGF2BP1	Overexpression	Poor							[59, 63]
HCC	WTAP	Overexpression	Poor					Prone		[64]
HCC	METTL14	Down-regulation	Better			Weaken	Decrease			[100]
HCC	YTHDF2	Overexpression	Poor	Microvascular invasion		Worsen				[65]
CRC	METTL3	Overexpression	Poor	Lymph node metastasis Liver metastasis Distant metastasis				Prone	Chemotherapy resistance	[67, 68, 70]
CRC	METTL3	Down-regulation	Better		Decrease					[103]
CRC	METTL14	Down-regulation	Better			Weaken	Decrease			[104]
CRC	FTO	Overexpression	Poor		Increase	Worsen				[71]
CRC	YTHDC2	Overexpression	Poor	Lymph node metastasis		Worsen				[74]
CRC	YTHDF1	Overexpression	Poor	Lymph node metastasis Distant metastasis		Worsen				[75]
CRC	IGF2BP2	Overexpression	Poor							[77]
PDAC	METTL3	Overexpression	Poor			Worsen				[78]
GC	METTL3	Overexpression	Poor							[80]
BCA	METTL3	Overexpression	Poor			Worsen	Increase			[82]
BCA	METTL14	Down-regulation	Better			Weaken				[106]
PCA	YTHDF2	Overexpression	Poor				Increase			[85]
RCC	METTL3	Down-regulation	Better		Decrease		Decrease			[107]
RCC	FTO	Down-regulation	Better			Weaken				[108]
RCC	WTAP	Overexpression	Poor		Increase	Worsen				[87]
CSCC	FTO	Overexpression	Poor			Worsen	Increase			[88]
BC	METTL3	Overexpression	Poor							[143]
BC	FTO	Overexpression	Poor				Increase			[94]
EOC	METTL3	Overexpression	Poor			Worsen	Increase			[95]
EOC	ALKBH5	Overexpression	Poor			Worsen	Increase			[96]
EOC	IGF2BP1	Overexpression	Poor							[59]
Melanoma	FTO	Overexpression	Poor			Worsen				[97]
Melanoma	YTHDF1	Down-regulation	Better			Weaken				[110]

AML acute myeloid leukemia; GBM glioblastoma; LC lung cancer; HCC hepatocellular carcinoma; CRC colorectal cancer; PDAC pancreatic cancer; GC gastric carcinoma; BCA bladder cancer; PCA prostate cancer; RCC renal cell carcinoma; CSCC cervical squamous cell carcinoma; BC breast cancer; EOC epithelial ovarian cancer

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com